North America SGLT2 Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 7.39 Billion |
| Market Size (2029) | USD 10.99 Billion |
| CAGR (2024 - 2029) | 8.67 % |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
North America SGLT2 Market Analysis
The North America Sodium-Dependent Glucose Co-Transporter 2 Market size is estimated at USD 7.39 billion in 2024, and is expected to reach USD 10.99 billion by 2029, growing at a CAGR of 8.67% during the forecast period (2024-2029).
COVID-19 significantly exacerbate Diabetes risks because the virus binds to pancreatic cells that produce insulin and could exert a toxic effect on them. In fact, they point out, studies of the earlier SARS-CoV-1 virus found that many infected patients had increased blood sugar. Drugmakers are rushing to advance potential treatments for the fast-spreading virus outbreak that has infected more people globally and so far, many were killed by the respiratory illness, according to a Reuters tally. SGLT2 inhibitors drug maker, AstraZeneca said 'it is committed to finding new solutions to fight COVID-19 by investigating the application of new and existing medicines.'
An FDA-approved group of prescription drugs known as SGLT2 inhibitors is used in combination with diet and exercise to decrease blood sugar levels in persons with type 2 diabetes. SGLT2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin as medications. They can be found as one-ingredient formulations or in mixtures with other diabetic medications like metformin. By encouraging the kidneys to eliminate sugar from the body through the urine, SGLT2 inhibitors reduce blood sugar levels. The FDA has not authorized SGLT2 inhibitors for use in individuals with type 1 diabetes because their safety and effectiveness in these patients have not been shown.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
North America SGLT2 Market Trends
Jardiance Drug Holds the Highest Share in The North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market
An oral diabetic medication called Jardiance aids in blood sugar regulation. The way empagliflozin works is by facilitating the kidneys' removal of glucose from circulation. For individuals with type-2 diabetes mellitus, Jardiance is taken in conjunction with diet and exercise to enhance blood sugar management. In individuals with type-2 diabetes and heart disease, Jardiance is used to reduce the risk of mortality from a heart attack, stroke, or heart failure. Adults with heart failure can also take Jardiance to lower their risk of cardiovascular mortality and hospitalization for heart failure (when the heart is frail and unable to pump enough blood to the body's other organs). The FDA approved Empagliflozin/Jardiance, the third SGLT inhibitor, in August 2014. It is recommended for type-2 DM patients who are adults to improve blood glucose control in addition to diet and exercise, reduce the risk of CV adverse events in type-2 DM subjects with an underlying CV illness, and reduce the risk of CV mortality and heart failure hospitalization in adults with an underlying heart failure and decreased EF. Ertugliflozin, the most recent SGLT inhibitor to get FDA approval, is suggested for adult individuals with type-2 DM to enhance blood glucose management in addition to diet and exercise.
The Jardiance group of products, managed in partnership with Eli Lilly, saw sales increase by 25.5% in 2021. Diabetes treatment is increasingly used to cut the risk of cardiovascular disease in diabetic patients and for the treatment of heart failure. Jardiance is granted the FDA Breakthrough Therapy designation and the FDA Fast Track designation. Submitted in the United States and Japan in January 2022. The FDA granted priority review for adults with heart failure independent of left ventricular ejection fraction.
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North America Sodium-Dependent Glucose Co-Transporter 2 (SGLT 2) Market Region.
The United States is Expected to Dominate the North America Sodium-Dependent Glucose Co-Transporter 2 (SGLT 2) Market
Due to its importance in glucose reabsorption, SGLT2 was identified as a promising pharmacological target in T2DM. While all SGLT2 inhibitors appear to be safe and effective for treating T2DM in patients, the most important difference among the individual agents is the uneven evidence base for use of these drugs as heart failure-specific therapy. The United States is considered to be a premium market space for most pharmaceutical companies, as they can price their drug at a high price than the other countries and still have high sales. The country's insurance policy, which reimburses close to 50% of the drug cost to the consumers, acts as a boon for pharmaceutical companies selling drugs. The United States is anticipated to dominate the market during the forecast period, owing to the rising prevalence of obesity in the Country. Due to changes in lifestyle and rising obesity rates, there has been a significant rise in diabetes prevalence in the United States during the past 20 years. Diabetes is one of the chronic diseases with the fastest rate of growth in the US. Each year, 1.75 million Americans receive a diabetes diagnosis. The nation also has the highest rate of obesity, a major contributor to Type 2 diabetes. Many health issues are related to diabetes. When the population with and without diabetes is compared, those who have diabetes have a 300% higher risk of being hospitalized and, as a result, spend more money on healthcare. The likelihood of COVID-19-related significant consequences is increased in diabetics.
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.
North America SGLT2 Industry Overview
The market studied is consolidated with Janssen Pharmaceutical, Eli Lilly, AstraZeneca Pharmaceuticals, and Boehringer Ingelheim Pharmaceuticals holding a high market share, followed by regional manufacturers accounting for a relatively smaller share.
North America SGLT2 Market Leaders
-
Janssen Pharmaceutical
-
Eli Lilly
-
AstraZeneca Pharmaceuticals
-
Boehringer Ingelheim Pharmaceuticals
-
Astellas
*Disclaimer: Major Players sorted in no particular order
North America SGLT2 Market News
- March 2022: Eli Lilly and Boehringer Ingelheim gained approval, for heart failure treatment from the EU for sodium-glucose co-transporter-2-inhibitor (SGLT2-I), Jardiance (empagliflozin). Previously Jardiance gained a label expansion for treating HF in the US.
- February 2022: The US Food and Drug Administration announced that empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) was approved for the treatment of patients with heart failure with preserved ejection (HFpEF), making it the first sodium-glucose cotransporter 2 (SGLT2) inhibitor to be cleared for these patients-a group for whom few treatments have proved effective.
North America SGLT2 Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Drug
- 5.1.1 Jardiance (Empagliflozin)
- 5.1.2 Farxiga/Forxiga (Dapagliflozin)
- 5.1.3 Invokana (Canagliflozin)
-
5.2 Geography
- 5.2.1 United States
- 5.2.2 Canada
- 5.2.3 Rest of North America
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Janssen Pharmaceutical
- 7.1.2 Boehringer Ingelheim Pharmaceuticals
- 7.1.3 AstraZeneca Pharmaceuticals
- 7.1.4 Eli Lilly
- 7.1.5 Astellas
- *List Not Exhaustive
-
7.2 COMPANY SHARE ANALYSIS
- 7.2.1 AstraZeneca Pharmaceuticals
- 7.2.2 Eli Lilly
- 7.2.3 Other Company Share Analyses
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityNorth America SGLT2 Industry Segmentation
A class of antihyperglycemic medications known as sodium-glucose co-transporter-2 (SGLT-2) inhibitors works by inhibiting the SGLT-2 proteins found in the renal proximal convoluted tubules. It works by preventing filtered glucose from being reabsorbed into the tubular lumen. North America's sodium-dependent glucose cotransporter 2 market witnessed USD 7.1 billion in the current year and is anticipated to register a CAGR of over 10% during the forecast period. The North American Sodium-dependent Glucose Cotransporter 2 Market is segmented by drugs (Invokana, Jardiance, and Farxiga/Forxiga) and geography (United States, Canada, and rest of North America). The report offers the value (in USD) and volume (in units) for the above segments. We will provide a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.
| Drug | Jardiance (Empagliflozin) |
| Farxiga/Forxiga (Dapagliflozin) | |
| Invokana (Canagliflozin) | |
| Geography | United States |
| Canada | |
| Rest of North America |
North America SGLT2 Market Research FAQs
How big is the North America Sodium-Dependent Glucose Co-Transporter 2 Market?
The North America Sodium-Dependent Glucose Co-Transporter 2 Market size is expected to reach USD 7.39 billion in 2024 and grow at a CAGR of 8.67% to reach USD 10.99 billion by 2029.
What is the current North America Sodium-Dependent Glucose Co-Transporter 2 Market size?
In 2024, the North America Sodium-Dependent Glucose Co-Transporter 2 Market size is expected to reach USD 7.39 billion.
Who are the key players in North America Sodium-Dependent Glucose Co-Transporter 2 Market?
Janssen Pharmaceutical, Eli Lilly, AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals and Astellas are the major companies operating in the North America Sodium-Dependent Glucose Co-Transporter 2 Market.
What years does this North America Sodium-Dependent Glucose Co-Transporter 2 Market cover, and what was the market size in 2023?
In 2023, the North America Sodium-Dependent Glucose Co-Transporter 2 Market size was estimated at USD 6.75 billion. The report covers the North America Sodium-Dependent Glucose Co-Transporter 2 Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Sodium-Dependent Glucose Co-Transporter 2 Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
North America SGLT2 Industry Report
Statistics for the 2024 North America SGLT2 market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America SGLT2 analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
